(Q33536633)

27 July 2017

1 reference

title

Sotalol: An important new antiarrhythmic (English)

1 reference

27 July 2017

Anderson JL

1

1 reference

27 July 2017

Prystowsky EN

series ordinal

2

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

27 July 2017

published in

American Heart Journal

1 reference

27 July 2017

volume

137

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

388-409

1 reference

Pharmacology, pharmacodynamics and pharmacokinetics of sotalol

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Clinical pharmacokinetics of sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Concentration/response relations for the multiple antiarrhythmic actions of sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Hemodynamic effects of intravenous and oral sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Hemodynamic studies with sotalol in man, performed at rest, during exercise, and during right ventricular pacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Sotalol exhibits reverse use-dependent action on monophasic action potentials in normal but not in infarcted canine ventricular myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiological effects of sotalol--just another beta blocker?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Sotalol-induced delayed ventricular repolarization in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Prolongation of the human cardiac monophasic action potential by sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Sotalol in patients with Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effects of intravenous sotalol in patients with atrioventricular accessory pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Reduction in QT dispersion by sotalol following myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden dea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Usefulness of sotalol for life-threatening ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

The ESVEM trial. Electrophysiologic Study Versus Electrocardiographic Monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. The ESVEM Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial. The ESVEM Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Controlled trial of sotalol for one year after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Dead is dead--artificial definitions are no substitute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Effect of sotalol on ventricular fibrillation and defibrillation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Sotalol for paroxysmal supraventricular tachycardias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

Clinical safety profile of sotalol in patients with arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970484-9

10.1016/S0002-8703(99)70484-9

7 January 2021

Identifiers

DOI

1 reference

27 July 2017

1 reference